Zydus Cadila gets final USFDA nod for hypertension drug
The drug will be marketed in strengths of 5 mg, 10mg22-08-2017
22-08-2017
Press Release / Media Release
Zydus receives final approval from the USFDA for Pindolol Tablets USP.22-08-2017
Zydus Cadila gets USFDA nod for hypertension drug
Zydus Cadila has received final approval from the US health regulator to market Telmisartan and Hydrochlorothiazide tablets used in the treatment of hypertension. The company has received final...17-08-2017
Press Release / Media Release
Zydus receives final approval from the USFDA for Telmisartan and Hydrochlorothiazide Tablets17-08-2017
Zydus Cadila gets USFDA nod for BP drug
The approval for Tiadylt ER extended release capsules is for multiple strengths of 120mg, 180mg, 240mg, 300mg and 420mg16-08-2017
Press Release / Media Release
Zydus receives final approval from the USFDA for Tiadylt ER Capsules and Azelastine Hydrochloride Nasal Spray16-08-2017
Company news
Cadila Healthcare on Monday said patent litigation relating to Aptalis' drug Canasa used for treatment of ulcerative colitis has been settled. As a result of the settlement, the company's US...14-08-2017
Press Release / Media Release
Zydus announces settlement with Aptalis on CANASA (mesalamine suppository, 1 g)14-08-2017
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Cadila Healthcare Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here13-08-2017
Updates
Voting Results of the 22nd Annual General Meeting of the Company held on August 11, 2017 as per Regulation 44 of the SEBI LODR.12-08-2017